Vadim Doronin

Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study

Michel Attal, Paul G. Richardson, S. Vincent Rajkumar et al. · The Lancet · 2019 · 636 citations

Medicine, Hematology, Pharmacotherapy +15

Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial

Sebastian Grosicki, Maryana Simonova, Ivan Špıčka et al. · The Lancet · 2020 · 324 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +16

Pevonedistat plus azacitidine vs azacitidine alone in higher-risk MDS/chronic myelomonocytic leukemia or low-blast-percentage AML

Lionel Adès, Larisa Girshova, Vadim Doronin et al. · Blood Advances · 2022 · 121 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +14

Enasidenib vs conventional care in older patients with late-stage mutant-<i>IDH2</i> relapsed/refractory AML: a randomized phase 3 trial

Stéphane de Botton, Pau Montesinos, Andre C. Schuh et al. · Blood · 2022 · 115 citations · Full text

Medicine, Oncology, Pharmacotherapy +14

Safety and efficacy of talacotuzumab plus decitabine or decitabine alone in patients with acute myeloid leukemia not eligible for chemotherapy: results from a multicenter, randomized, phase 2/3 study

Pau Montesinos, Gail J. Roboz, Claude‐Eric Bulabois et al. · Leukemia · 2020 · 102 citations · Full text

Medicine, Oncology, Pharmacology +12